Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening - a consensus statement from the Korean Society of Gynecologic Oncology

Q: What is the purpose of this consensus clinical practice guideline?

It provides standardized recommendations to support consistent and rational implementation of hrHPV testing in cervical cancer screening in Korea.

Q: For whom may hrHPV testing be considered, and what screening interval is recommended?

HrHPV testing may be considered for women aged 25 years or older, with a recommended screening interval of 3 to less than 5 years.

Q: What assay and reporting requirements are emphasized for hrHPV testing?

Screening assays should differentiate HPV genotypes 16 and 18 and detect other high-risk types, and testing should be done with standardized specimen handling and documentation of HPV 16/18 status in positive cases.

Sep 23, 2026

Uploaded by Margaret

High-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer, and hrHPV testing has become an effective screening option that addresses limitations of cytology-based screening. This consensus-based clinical practice guideline was developed by the Korean Society of Gynecologic Oncology using systematic review of domestic and international evidence and input from multidisciplinary public hearings. Expert consensus produced four key recommendations on eligibility age, testing interval, assay requirements for HPV genotypes 16/18 and other high-risk types, and standardized testing conditions with rigorous internal and external quality control to support consistent implementation in Korea.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

Keywords

Meeting report

Correspondence and authors

Funding and conflict of interest

Data availability

Author contributions

J Gynecol Oncol. 2026 Mar;37(2):e90 [https://doi.org/10.3802/jgo.2026.37.e90](https://doi.org/10.3802/jgo.2026.37.e90)[ ](https://doi.org/10.3802/jgo.2026.37.e90)pISSN 2005-0380·eISSN 2005-0399 Meeting Report Received: Jan 29, 2026 Accepted: Jan 31, 2026 Published online: Mar 1, 2026 Correspondence to Shin-Wha Lee Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Email: [swhlee@amc.seoul.kr](swhlee@amc.seoul.kr) Jaeman Bae Department of Obstetrics and Gynecology, Hanyang University Medical Center, 222-1 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea. [Email: obgybae@hanyang.ac.kr](Email: obgybae@hanyang.ac.kr) © 2026. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ORCID iDs Ju-Hyun Kim [https://orcid.org/0000-0003-4007-5739](https://orcid.org/0000-0003-4007-5739)[ ](https://orcid.org/0000-0003-4007-5739)[Seung-Hyuk Shim](Seung-Hyuk Shim) [https://orcid.org/0000-0001-8043-2257](https://orcid.org/0000-0001-8043-2257)[ ](https://orcid.org/0000-0001-8043-2257)[Kyung-Jin Min](Kyung-Jin Min) [https://orcid.org/0000-0002-5783-4968](https://orcid.org/0000-0002-5783-4968) Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology Ju-Hyun Kim ,1 Seung-Hyuk Shim ,2 Kyung-Jin Min ,3 Jae-Kwan Lee ,4 Chong Woo Yoo ,5 Min-Jung Kwon ,6 Shin-Wha Lee ,1 Jaeman Bae 7 1Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 2Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea 3Department of Obstetrics and Gynecology, Korea University Ansan Hospital, Ansan, Korea 4Department of Obstetrics and Gynecology, Korea University Guro Hospital, Seoul, Korea 5Department of Pathology, National Cancer Center, Goyang, Korea 6Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea 7Department of Obstetrics and Gynecology, Hanyang University Medical Center, Seoul, Korea ABSTRACT High-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer, and hrHPV testing has increasingly been recognized as an effective screening tool that overcomes the limitations of cytology-based screening. However, standardized clinical guidance for the use of hrHPV testing in cervical cancer screening has been limited in Korea, resulting in variability in clinical practice. This consensus-based clinical practice guideline was developed under the auspices of the Korean Society of Gynecologic Oncology through multidisciplinary collaboration involving experts in gynecology, pathology, laboratory medicine, and public health. Relevant domestic and international evidence was systematically reviewed, and input from diverse clinical settings was incorporated through four public hearings. Final recommendations were established through expert consensus. The guideline presents four key recommendations: hrHPV testing may be considered for women aged 25 years or older, with a recommended screening interval of 3 to <5 years; screening assays should differentiate HPV genotypes 16 and 18 and detect other high-risk types, with preference given to clinically validated tests; testing should be performed in appropriately equipped settings with standardized specimen handling and reportin

FAQs

What is the purpose of this consensus clinical practice guideline?

It provides standardized recommendations to support consistent and rational implementation of hrHPV testing in cervical cancer screening in Korea.

For whom may hrHPV testing be considered, and what screening interval is recommended?

HrHPV testing may be considered for women aged 25 years or older, with a recommended screening interval of 3 to less than 5 years.

What assay and reporting requirements are emphasized for hrHPV testing?

Screening assays should differentiate HPV genotypes 16 and 18 and detect other high-risk types, and testing should be done with standardized specimen handling and documentation of HPV 16/18 status in positive cases.

Sep 23, 2026

Uploaded by Margaret